Trial Profile
The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC Receiving Gemcitabine and Cisplatin or Carboplatin Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Jan 2017
Price :
$35
*
At a glance
- Drugs Oprelvekin (Primary) ; Thrombopoietin (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- Sponsors 3SBio; Shenyang Sunshine Pharmaceutical
- 02 Feb 2015 New trial record